Overview
Adenocarcinoma of the lung is a type of non-small cell lung cancer that arises from glandular epithelial cells, typically those involved in producing mucus or lining the distal airways and alveoli. It is the most common histological form of lung cancer in many populations, including among individuals who have never smoked, and tends to develop in the peripheral regions of the lung. Histologically it is recognized by gland formation, papillary or lepidic growth patterns, and mucin production, with subtypes ranging from indolent in situ lesions to invasive disease. A defining feature of pulmonary adenocarcinoma is its association with actionable molecular alterations, including mutations in the epidermal growth factor receptor, rearrangements of ALK and ROS1, and other driver changes that have become central to treatment selection. Tumors may grow and spread for a prolonged period before producing symptoms such as persistent cough, dyspnea, chest discomfort, or signs of metastasis. Diagnosis combines imaging, biopsy, and increasingly comprehensive molecular profiling alongside testing for immunotherapy biomarkers. Treatment is stage-dependent and may include surgical resection, radiation, cytotoxic chemotherapy, targeted agents directed at specific driver mutations, and immune checkpoint inhibitors. Continued research into tumor genomics, resistance pathways, and early detection aims to improve outcomes in this clinically and molecularly heterogeneous disease.
Research published in this journal
5 peer-reviewed articles, ranked by relevance. Each links to its DOI.
The Bromine, Calcium, Potassium, Magnesium, Manganese, and Sodium Contents in Adenocarcinoma of Human Prostate Gland
Impact of Biofield Energy Treatment Based Test Formulation on Vital Organ Health Specific Biomarkers Using Cell Line Study
Thyroid Transcription Factor-1 Activity is Required for the Proliferation of Human Thyroid Cancer Cells 8505C
The Current Immunoassays and Emerging Immunogenomic Approaches for Immunomonitoring Cancer and Infectious Diseases
How this research is being cited
The 5 articles above have been cited 33 times in the scholarly literature. Citation data via OpenAlex and Crossref, updated Jun 2026.
-
Jaekwon Seok et al. · 2023 · Journal of Translational Medicine
-
CFTR-mediated monocyte/macrophage dysfunction revealed by cystic fibrosis proband-parent comparisons2022 · JCI Insight
-
2022 · Cancers
-
2022 · Cancers
-
Iman Ehsan et al. · 2022 · Journal of Drug Delivery Science and Technology
-
CFTR-mediated monocyte/macrophage dysfunction revealed by cystic fibrosis proband-parent comparisons2022 · JCI Insight
-
2021 · medRxiv (Cold Spring Harbor Laboratory)
-
CFTR-mediated monocyte-macrophage dysfunction revealed by cystic fibrosis proband-parent comparisonsX. Zhang et al. · 2021 · medRxiv
A sample of recent works citing this journal's research on Adenocarcinoma of the Lung, linking to each citing work.